FDA Approves New Treatment for Refractory HSV in Immunocompromised Adults

The FDA has approved HOVILPRI (pritelivir) 100 mg tablets for mucocutaneous lesions caused by herpes simplex virus that are resistant to standard antiviral treatments in immunocompromised adults. This marks the first new mechanism of action for an HSV therapy in nearly 30 years, offering a new option for a vulnerable patient population.